{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:08:18Z","timestamp":1771466898177,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":79,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["2020B010188001"],"award-info":[{"award-number":["2020B010188001"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102080325"],"award-info":[{"award-number":["202102080325"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.crphar.2022.100098","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T01:26:06Z","timestamp":1648344366000},"page":"100098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate"],"prefix":"10.1016","volume":"3","author":[{"given":"Yuanyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.crphar.2022.100098_bib1","first-page":"760","article-title":"Hyperuricemia and gout; the role of diet","volume":"29","author":"\u00c1lvarez-Lario","year":"2014","journal-title":"Nutr. Hosp."},{"key":"10.1016\/j.crphar.2022.100098_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia","volume":"294","author":"Cabau","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.crphar.2022.100098_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/md17060343","article-title":"Preventive effects of fucoidan and fucoxanthin on hyperuricemic rats induced by potassium oxonate","volume":"17","author":"Chau","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.crphar.2022.100098_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.1377","article-title":"Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population-based cohort study and meta-analysis","volume":"106","author":"Chen","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.crphar.2022.100098_bib5","doi-asserted-by":"crossref","first-page":"109195","DOI":"10.1016\/j.biopha.2019.109195","article-title":"Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice","volume":"118","author":"Chen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.crphar.2022.100098_bib6","doi-asserted-by":"crossref","first-page":"153111","DOI":"10.1016\/j.phymed.2019.153111","article-title":"Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption","volume":"66","author":"Cui","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.crphar.2022.100098_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.crphar.2022.100098_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202901","article-title":"Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage","volume":"13","author":"Garcia-Arroyo","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.crphar.2022.100098_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12902-021-00698-6","article-title":"Uric acid-induced pancreatic \u03b2-cell dysfunction","volume":"21","author":"Ghasemi","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.crphar.2022.100098_bib10","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.2174\/138161205774913255","article-title":"Uric acid and oxidative stress","volume":"11","author":"Glantzounis","year":"2005","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.crphar.2022.100098_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijcard.2015.08.087","article-title":"The treatment of hyperuricemia","volume":"213","author":"Gliozzi","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.crphar.2022.100098_bib12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ptr.3421","article-title":"Hypouricemic effects of anthocyanin extracts of purple sweet potato on potassium oxonate-induced hyperuricemia in mice","volume":"25","author":"Hwa","year":"2011","journal-title":"Phytother Res."},{"key":"10.1016\/j.crphar.2022.100098_bib13","doi-asserted-by":"crossref","first-page":"3732317","DOI":"10.1155\/2021\/3732317","article-title":"Antihyperuricemic effect of dendropanax morbifera leaf extract in rodent models","volume":"2021","author":"Lee","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.crphar.2022.100098_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014928","article-title":"Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements","volume":"7","author":"Li","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.crphar.2022.100098_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejmech.2017.08.047","article-title":"Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors","volume":"140","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.crphar.2022.100098_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","article-title":"Regulation of uric acid excretion by the kidney","volume":"14","author":"Lipkowitz","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.crphar.2022.100098_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2337\/db19-0704","article-title":"Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic \u03b2-cell death in uricase-deficient male mice","volume":"69","author":"Lu","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.crphar.2022.100098_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107882","article-title":"Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study","volume":"9","author":"Miyake","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.crphar.2022.100098_bib19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia","volume":"23","author":"S\u00e1nchez-Lozada","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.crphar.2022.100098_bib20","first-page":"223","article-title":"The optimization and assessment of the method for inducing hyperuricemia in rats","volume":"36","author":"Shi","year":"2020","journal-title":"Chin. J. Physiol."},{"key":"10.1016\/j.crphar.2022.100098_bib21","doi-asserted-by":"crossref","first-page":"5817348","DOI":"10.1155\/2020\/5817348","article-title":"Research advances in the mechanisms of hyperuricemia-induced renal injury","volume":"2020","author":"Su","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.crphar.2022.100098_bib22","article-title":"Febuxostat for treating chronic gout","volume":"11","author":"Tayar","year":"2012","journal-title":"Cochrane"},{"key":"10.1016\/j.crphar.2022.100098_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.biopha.2018.02.010","article-title":"RIP3-deficience attenuates potassium oxonate-induced hyperuricemia and kidney injury","volume":"101","author":"Wang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.crphar.2022.100098_bib24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.crphar.2022.100098_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2015.08.110","article-title":"Filippatos, Relation of serum uric acid to cardiovascular disease","volume":"213","author":"Wu","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.crphar.2022.100098_bib26","article-title":"Anti-hyperuricemic and nephroprotective effects of dihydroberberine in potassium oxonate- and hypoxanthine-induced hyperuricemic mice","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.crphar.2022.100098_bib27","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/1440-1681.13374","article-title":"Serum uric acid and incident atrial fibrillation: a systematic review and dose-response meta-analysis","volume":"47","author":"Zhang","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.crphar.2022.100098_bib28","doi-asserted-by":"crossref","first-page":"110795","DOI":"10.1016\/j.biopha.2020.110795","article-title":"Recent advances in fructose intake and risk of hyperuricemia","volume":"131","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.crphar.2022.100098_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4727","article-title":"Anti-hyperuricemia activity and toxicity prediction of a novel xanthine oxidoreductase inhibitor","volume":"34","author":"Zhou","year":"2020","journal-title":"Biomed. Chromatogr. : BMC (Biomed. Chromatogr.)"},{"key":"10.1016\/j.crphar.2022.100098_bib30","doi-asserted-by":"crossref","first-page":"114246","DOI":"10.1016\/j.ab.2021.114246","article-title":"Development of a fluorescence-based assay for screening of urate transporter 1 inhibitors using 6-carboxyfluorescein","volume":"626","author":"Zhou","year":"2021","journal-title":"Anal. Biochem."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257122000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257122000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:50:28Z","timestamp":1762923028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257122000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":30,"alternative-id":["S2590257122000189"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2022.100098","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2022.100098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100098"}}